Last reviewed · How we verify
Furozin (CARPRONIUM)
Furozin (generic name: CARPRONIUM) is a carpronium drug. It is currently in Phase 2 development.
Furozin is thought to work by interacting with a specific biological target, although the exact nature of this interaction is not well understood.
Furozin, also known as Carpronium, is a small molecule drug in the carpronium class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Furozin is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety and efficacy. As a result, Furozin is not currently a viable treatment option.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CARPRONIUM |
|---|---|
| Drug class | carpronium |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and Furozin is a key that fits into one of these locks. When Furozin binds to its target, it can either block or enhance the activity of the cell, depending on the specific lock and key interaction. This can lead to changes in the way the cell functions, which may help to treat certain diseases.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furozin CI brief — competitive landscape report
- Furozin updates RSS · CI watch RSS
Frequently asked questions about Furozin
What is Furozin?
How does Furozin work?
What is the generic name of Furozin?
What drug class is Furozin in?
What development phase is Furozin in?
Related
- Drug class: All carpronium drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing